EUVIMEDEUVIMED entdecken
Multizentrische Studie

Elevated lipoprotein(a) and prevalent cardiovascular disease burden in treated hypertension

Nicolás F Renna, Matías Arrupe, Juan Bautista Soumoulou, Santiago Lynch, Federico Salazar, Ezequiel Forte, Flavia Salati, Sergio Giménez, Augusto Lavalle-Cobo, Gustavo Lavenia, María Gabriela Matta, Laura Schreier und 1 weitere

Journal of Clinical Lipidology · 2026

DOI: 10.1016/j.jacl.2026.08.008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Nicolás F Renna und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Español de Mendoza, Mendoza, Argentina (Renna and Arrupe); Area of Physiopathology, Department of Basic Sciences i…. Hauptthemen laut MEDLINE: Lipoprotein(a), Hypertension, Cardiovascular Diseases. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Universidad Nacional de Cuyo, National University of Cuyo Office of Research International and Postgraduate Studies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease across multiple clinical settings, but its relationship with prevalent cardiovascular disease burden among adults with treated hypertension (HTN) remains incompletely characterized. OBJECTIVE: To evaluate the association between elevated Lp(a) levels and prevalent cardiovascular disease burden among adults with treated HTN after adjustment for contemporaneous office blood pressure (BP) control. METHODS: We performed a predefined cross-sectional subanalysis of the multicenter Argentine Group for the Study of Lp(a) cohort, including adults with treated HTN and available Lp(a) measurements. BP control was defined as office BP ≤130/80 mmHg. Lp(a) was analyzed as a continuous variable using a high-risk threshold of ≥125 nmol/L. Multivariable generalized estimating equation models adjusted for age, sex, diabetes mellitus, smoking status, low-density lipoprotein-cholesterol, statin therapy, and BP control were used to evaluate the association between Lp(a) and prevalent cardiovascular disease burden. RESULTS: Among 2313 patients with treated HTN, higher Lp(a) levels were independently associated with a greater prevalence of cardiovascular disease burden. Each 1-SD increase in log-transformed Lp(a) was associated with higher odds of prevalent cardiovascular disease burden (Odds ratio [OR] 1.24; 95% CI 1.09-1.41; P = 0.001). Participants with Lp(a) ≥125 nmol/L had significantly higher odds of prevalent cardiovascular disease burden (OR 1.38; 95% CI 1.02-1.88; P = 0.037). Additional adjustment for body mass index and ethnicity yielded consistent results. No significant interaction was observed between Lp(a) levels and BP control status. CONCLUSION: In adults with treated HTN, elevated Lp(a) was independently associated with prevalent cardiovascular disease burden after adjustment for office BP control and conventional cardiovascular risk factors. These findings support the potential role of Lp(a) assessment in refining cardiovascular risk stratification in treated hypertensive populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)HypertensionCardiovascular DiseasesHumansFemaleMaleMiddle AgedCross-Sectional StudiesPrevalenceBlood PressureAgedRisk Factors

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseBlood pressure controlCardiovascular disease burdenHypertensionLipoprotein(a)Statin therapy

Substanzen

Lipoprotein(a)

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Español de Mendoza, Mendoza, Argentina (Renna and Arrupe); Area of Physiopathology, Department of Basic Sciences in Health, UNCuyo-IMBECU-CONICET, Mendoza, Argentina (Renna). Electroni…
  • Department of Cardiology, Hospital Español de Mendoza, Mendoza, Argentina (Renna and Arrupe).
  • Department of Cardiology, Centro Los Pilares, Chubut, Argentina (Soumoulou).
  • Department of Cardiology, Instituto Cardiovascular San Isidro (ICSI), Buenos Aires, Argentina (Lynch).
  • Department of Cardiology, Hospital Privado de Comunidad, Mar del Plata, Argentina (Salazar).
  • Department of Cardiology, Centro Diagnóstico Cardiovascular CENDIC, Entre Rios, Argentina (Forte).

Förderung

  • Universidad Nacional de Cuyo
  • National University of Cuyo Office of Research International and Postgraduate Studies

Zitieren

APA

Renna, N. F., Arrupe, M., Soumoulou, J. B., Lynch, S., Salazar, F., Forte, E., Salati, F., Giménez, S., Lavalle-Cobo, A., Lavenia, G., Matta, M. G., Schreier, L., & Corral, P. (2026). Elevated lipoprotein(a) and prevalent cardiovascular disease burden in treated hypertension. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.08.008

Vancouver

Renna NF, Arrupe M, Soumoulou JB, Lynch S, Salazar F, Forte E, et al. Elevated lipoprotein(a) and prevalent cardiovascular disease burden in treated hypertension. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.08.008

BibTeX
@article{Renna2026,
  author = {Renna, Nicolás F and Arrupe, Matías and Soumoulou, Juan Bautista and Lynch, Santiago and Salazar, Federico and Forte, Ezequiel and Salati, Flavia and Giménez, Sergio and Lavalle-Cobo, Augusto and Lavenia, Gustavo and Matta, María Gabriela and Schreier, Laura and Corral, Pablo},
  title = {Elevated lipoprotein(a) and prevalent cardiovascular disease burden in treated hypertension},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  doi = {10.1016/j.jacl.2026.08.008}
}
Kostenlos starten →